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Improving the reporting of animal research: when
will we ARRIVE?
Nathalie Percie du Sert1
Many factors can influence the outcome and interpretation of
experiments using animals – from the strain or sex of the animal
through to choosing the correct statistical method for analysis. You
would therefore expect such information to be readily available in
all publications reporting in vivo research, wouldn’t you?
However, this is not the case, according to a recent study
published by the National Centre for the Replacement, Refinement
and Reduction of Animals in Research (NC3Rs). In the largest
survey of its kind, the NC3Rs reviewed 271 publications describing
experiments involving rodents and non-human primates in
biomedical research; all were publicly funded studies carried out
in the US or the UK. Our analysis showed that only 60% of the
articles stated the number and characteristics of the animals used
(i.e. strain, sex and age or weight). Only 70% of the publications
that used statistical methods fully described them and presented
the results with a measure of precision or variability. In many
papers, it was difficult to assess whether the statistical analysis was
appropriate because information detailing the statistical methods
was lacking. Most of the papers did not report the use of
randomisation (87%) or blinding (86%) to
reduce bias in animal selection and outcome
assessment (Kilkenny et al., 2009).
Scientific progress relies on adding to the
knowledge base by communication within the
scientific community, usually through peer-
reviewed publication. Failure to report all
essential information therefore reduces the
utility of the knowledge base that is used to
inform subsequent studies, making it difficult
to build on or reproduce experiments, allow
novel methods to be used or carry out
retrospective analyses of data. It also brings into
question the peer-review process – the quality control applied by
most journals – because scientific rigour cannot be assured if there
is not the information to assess whether the experiment was
properly designed, executed and analysed.
In the context of animal research, inadequate reporting raises
ethical as well as scientific concerns. Incomplete reporting of in
vivo research might hinder the translation of experimental
findings to humans by restricting the potential use of systematic
reviews and meta-analyses to assess preclinical evidence. For
example, in a meta-analysis looking at animal models of multiple
sclerosis, a substantial number of studies could not be included
because results were poorly reported (Vesterinen et al., 2010).
There are also concerns that information about the age or sex of
the animals used, which should be considered before deciding
whether a drug should progress to clinical trials, especially if the
condition that the drug is proposed to treat is gender specific or
affects a particular age class, is not readily reported. Missing
information reduces the value gained from animal experiments,
which can result in unnecessary additional studies and financial
expense – neither of which is desirable, particularly in the current
climate.
ARRIVE-ing at a solution
So, what is the solution? The NC3Rs recently published new
guidelines aimed at providing a steer to improve the reporting of
animal experiments (Kilkenny et al., 2010). The guidelines, called
ARRIVE (Animal Research: Reporting of In Vivo Experiments),
were developed and ‘road tested’ in collaboration with scientists,
statisticians, journal editors and research funders, and consist of a
checklist of 20 items that represent the key
information that is  necessary to describe a
study in a comprehensive and transparent
manner. The ARRIVE guidelines cover the
main aspects of  a  scientific publication and
make recommendations on the reporting of the
study design, experimental procedures, animal
characteristics, housing and husbandry, and
statistical analysis. From an author’s
perspective, applying these guidelines carefully
is an opportunity to make the most out of one’s
own work, ensuring that it provides real value
to the scientific landscape and is used by others.
The intention of ARRIVE is to maximise the output of research
that uses animals. Achieving this will benefit the whole scientific
community. The success of such an approach has already been
demonstrated for clinical research, where guidelines were
developed to address concerns regarding the poor reporting of
randomised control trials (RCTs) (Moher et al., 1994). The so-called
CONSORT statement (Begg et al., 1996; Schulz et al., 2010) was
drafted by an expert working group composed of editors, clinical
epidemiologists and statisticians, and was subsequently endorsed
by many journals. These guidelines have contributed significantly
to improving RCT reports (Plint et al., 2006).
Evolution and impact of ARRIVE
The ARRIVE guidelines were simultaneously published in eight
bioscience journals in 2010 and, since then, almost 40 journals
have adopted them (the full list can be found on the NC3Rs website
at http://www.nc3rs.org.uk/ARRIVE), e.g. by including a link to
the guidelines in their instructions to authors. A study looking at
the impact of CONSORT two years following its publication found
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that, even though all journals that were analysed had improved
reporting of RCTs over time, reporting quality was significantly
higher in journals that had endorsed the reporting guidelines
(Moher et al., 2001). This is our objective with the ARRIVE
guidelines: we will assess whether and how they change the
reporting of animal research in the next few years. There are, of
course, hundreds of bioscience journals worldwide, and there is a
long way to go in terms of our ambition of universal support and
uptake.
The ARRIVE guidelines were developed as a consensus and
should evolve as a consensus. As such, experience and feedback
are essential in determining whether they should be improved and,
if so, how. The impact and evolution of the ARRIVE guidelines
rests on the collective efforts of authors, peer reviewers, journal
editors, publishers and funding bodies to disseminate, endorse and
apply them. To do otherwise should be unsustainable at a time when
there is increased pressure on resources and a greater expectation
that research will be exploited.
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